Zixin pharmaceutical plans to acquire 67% equity of gene sequencing company of the United States for us $42 million

Source: china.com.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn.cn Zixin pharmaceutical plans to sign the investment framework agreement with nabsys 2.0, through the first capital increase of 6 million US dollars or equivalent RMB, and up to 36 million US dollars or equivalent RMB for follow-up investment, totaling 42 million US dollars or equivalent RMB, and finally owns 67% equity of nabsys 2.0 According to the announcement data, nabsys 2.0 is a limited liability company registered in Delaware, USA It is a research innovation company that integrates the advantages of the fourth generation DNA analysis system in R & D, production, sales, professional knowledge, advanced equipment, etc., and has strong knowledge and experience in basic research and applied scientific research It has carried out DNA research by electronic methods It won the "1000 genome" award from the National Institute of human genome, NIH The fourth generation DNA analysis system developed by nabsys 2.0 integrates pure solid-state, microelectronics, single molecule sequencing analysis and many advanced technologies in many fields, and analyzes the electronic map of long-chain DNA molecules and the whole genome with a resolution significantly higher than that of optical methods It realizes the accurate sequence of gene fragments, the precise location of fragments in the genome, and the analysis of large-scale genome structural variation, so as to obtain the whole genome information Zixin pharmaceutical said that the fourth generation DNA analysis system developed by nabsys 2.0 integrates pure solid-state, microelectronics, single molecule sequencing analysis and advanced technologies in many fields to analyze the electronic map of long-chain DNA molecules and the whole genome with a resolution significantly higher than that of optical methods It realizes the accurate sequence of gene fragments, the precise location of fragments in the genome, and the analysis of large-scale genome structural variation, so as to obtain the whole genome information At the same time, the company plans to acquire nabsys 2.0 to get a close understanding of and familiar with the chief experts in the field of gene sequencer and their basic and clinical application views, acquire the operation and rules of international innovation projects, and make the company's gene sequencer technology and the fourth generation DNA The full and effective combination of the analysis system will contribute to the future development and effective complementarity of the company's gene sequencer technology, promote the research and development of the company's new generation of gene sequencer, and further advance the internationalization of the research and development of Zixin pharmaceutical industry Zixin pharmaceutical pointed out that the proposed investment in nabsys 2.0 is one of the important measures for the company to implement the international development strategy, which is conducive to accelerating the pace of the company's international strategy in the field of gene sequencer, laying the foundation for Zixin pharmaceutical to achieve the international strategic goal, strengthening the company's exchange and cooperation with the international market, and expanding the U.S market and the global market Accelerate the international operation of the company's brand, production, talent and technology, enhance the brand image and further enhance the company's core competitiveness In addition, the announcement also said that the board of directors of Zixin pharmaceutical also considered and passed the proposal on the investment of wholly-owned subsidiaries to establish a holding company and the proposal on the injection and deep processing construction projects of wholly-owned subsidiaries of the company The board of directors of Zixin pharmaceutical agrees that Jilin Zixin Prajna Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, and Jilin tianzuodong Agricultural Technology Co., Ltd intend to jointly invest to establish Jilin Zixin shuosheng Agricultural Development Co., Ltd The company's registered capital is proposed to be 5 million yuan, and Jilin Zixin Prajna Pharmaceutical Co., Ltd contributes 3.5 million yuan with its own capital, accounting for 70% of the total investment According to the announcement, in view of the rapid development of the injection industry at present, Zixin pharmaceutical agreed to accelerate the upgrading of the industry, improve the company's core competitiveness in this field, promote the upgrading of the company's pharmaceutical industry, enable the company to enter a new development platform, achieve sustainable development, and rapidly transform the developed products into large-scale production and form a large-scale operation Construction and implementation of injection and ginseng deep processing project of linzixin Prajna Pharmaceutical Co., Ltd